Search results for "Highlights"


 
Results 61 - 70 of about 300 for "Highlights".

Rates of diabetes-related ESRD appear to decrease in U.S., Puerto Rico

From 2000 to 2014, the age-standardized incidence of end-stage renal disease (ESRD) attributed to diabetes decreased from 260.2 to 173.9 per 100,000 diabetic population.
November 2017

Type 1 diabetes associated with increased atrial fibrillation risk, particularly in women

Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.
September 2017

Tool may help stratify risk for hypoglycemia-related ED and hospital use

The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
September 2017

No increase in mortality with incretin-based drugs compared to other diabetes meds, review finds

The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
July 2017

Glucose self-monitoring had no effect on glycemic control in non–insulin-treated type 2 diabetes

Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.
July 2017

Cardiovascular disease and mortality appear lower in patients on SGLT2 inhibitors

The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
August 2017

Metformin appears to prevent type 2 diabetes, study indicates

Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
August 2017

Dapagliflozin appears effective as adjunct therapy in patients with type 1 diabetes

Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
October 2017

Highlights

The frequency of diabetes visits varied across health systems, but within most of the studied organizations, patients with high HbA1c levels were not seen any more often than those with lower levels.
December 2019

SGLT2 inhibitors may have class effect for reduction of cardiac risk

The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
June 2017

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next